Litchfield Caroline's Insider Trades & SAST Disclosures
Litchfield Caroline's most recent trade in Merck & Co Inc was a trade of 53,735 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 29, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Litchfield Caroline.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co Inc | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 53,735 | 53,735 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 11,805 | 11,805 | - | - | Restricted Stock Unit | |
| Verizon Communications Inc | Caroline A. Litchfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 4,748 | 5,948 | - | - | Phantom Stock | |
| Merck & Co Inc | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 97.94 per share. | 27 Jan 2025 | 23,432 | 74,340 (0%) | 0% | 97.9 | 2,294,930 | Common Stock |
| Verizon Communications Inc | Caroline A. Litchfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 1,161 | 1,161 | - | - | Phantom Stock | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 49,805 | 49,805 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Litchfield Caroline | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.08 per share. | 14 Feb 2024 | 38,291 | 89,199 (0%) | 0% | 58.1 | 2,223,941 | Common Stock |
| Merck & Co Inc | Litchfield Caroline | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 38,291 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Sale of securities on an exchange or to another person at price $ 125.50 per share. | 14 Feb 2024 | 38,291 | 50,908 (0%) | 0% | 125.5 | 4,805,521 | Common Stock |
| Merck & Co Inc | Litchfield Caroline | EVP & CFO | Grant, award, or other acquisition of securities at price $ 119.43 per share. | 22 Jan 2024 | 19,208 | 50,908 (0%) | 0% | 119.4 | 2,294,011 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 58,783 | 58,783 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 866 | 0 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.47 per share. | 01 May 2023 | 866 | 32,118 (0%) | 0% | 115.5 | 99,997 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.47 per share. | 01 May 2023 | 427 | 31,691 (0%) | 0% | 115.5 | 49,306 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 109.88 per share. | 23 Jan 2023 | 2,656 | 30,186 (0%) | 0% | 109.9 | 291,841 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 53,398 | 53,398 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.65 per share. | 03 May 2022 | 773 | 27,799 (0%) | 0% | 87.6 | 67,753 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 773 | 0 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.65 per share. | 03 May 2022 | 373 | 27,426 (0%) | 0% | 87.6 | 32,693 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.69 per share. | 01 May 2022 | 866 | 27,453 (0%) | 0% | 88.7 | 76,806 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 866 | 866 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.69 per share. | 01 May 2022 | 427 | 27,026 (0%) | 0% | 88.7 | 37,871 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 73.51 per share. | 24 Feb 2022 | 2,429 | 26,555 (0%) | 0% | 73.5 | 178,556 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 22,683 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 22,683 | 42,448 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Sale of securities on an exchange or to another person at price $ 91.00 per share. | 04 Nov 2021 | 18,335 | 24,113 (0%) | 0% | 91.0 | 1,668,503 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 67,347 | 67,347 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 75.98 per share. | 04 May 2021 | 1,039 | 20,230 (0%) | 0% | 76.0 | 78,943 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2021 | 1,039 | 0 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.98 per share. | 04 May 2021 | 489 | 19,741 (0%) | 0% | 76.0 | 37,154 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 840 | 1,680 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.50 per share. | 01 May 2021 | 840 | 19,082 (0%) | 0% | 74.5 | 62,580 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 750 | 750 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.50 per share. | 01 May 2021 | 750 | 19,544 (0%) | 0% | 74.5 | 55,875 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.50 per share. | 01 May 2021 | 353 | 19,191 (0%) | 0% | 74.5 | 26,299 | Common Stock |
| Merck & Co Inc | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.50 per share. | 01 May 2021 | 288 | 18,794 (0%) | 0% | 74.5 | 21,456 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges